Skip to main
LRMR

LRMR Stock Forecast & Price Target

LRMR Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 71%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Larimar Therapeutics is projected to have a strong launch with the potential for high revenues from their flagship product nomlabofusp due to its positive efficacy data and clinical improvements. Their recent updates have maintained their launch timing for the product and highlighted the potential for successful FDA review and approval. However, there may be a risk of delays or termination of development due to the need for external funding.

Bears say

Larimar Therapeutics is currently not a financially viable company, as it heavily relies on one product, nomlabofusp, for its success. There are also safety concerns regarding potential anaphylaxis reactions from the product and the company's lack of clarity on how to handle them. Additionally, competition from established company Biogen and other emerging gene therapies could further hinder Larimar's success.

LRMR has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 71% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Larimar Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Larimar Therapeutics Inc (LRMR) Forecast

Analysts have given LRMR a Buy based on their latest research and market trends.

According to 7 analysts, LRMR has a Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.57, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.57, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Larimar Therapeutics Inc (LRMR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.